LOS ANGELES– SpineX Inc., a clinical stage bioelectric medtech company, has had an important publication accepted in the prestigious Journal of Urology. The publication, entitled A Pilot Study of the Effect of Transcutaneous Spinal Cord Stimulation on Micturition-Related Brain Activity and Lower Urinary Tract Symptoms after Stroke shows improved bladder function and restoration of brain activity associated with normal voiding in stroke survivors who completed SpineX SCONE™ therapy.
“This is a significant advancement in our research,” says Dr. Evgeniy Kreydin, SpineX’s co-founder and Chief Medical Officer, and an adjunct assistant professor of clinical urology at the University of Southern California. “We are able to show clinical evidence that our technology can make a difference in the lives of stroke patients.”
Improved bladder function is a high priority for stroke survivors, affording the ability to sleep longer periods of time, drive longer distances and live fuller lives – all important advances that align with SpineX’s key mission to improve the lives of people living with neurological conditions. The publication demonstrates that SCONE therapy corrects brain activity changes after stroke, bringing post-stroke brain activity associated with bladder control to a level similar to that of healthy individuals. This improved brain function is directly associated with clinically significant improvement in bladder function.
“We’re moving forward rapidly with this technology,” confirms Kreydin. “Right now we’re recruiting for a clinical trial with our SCONE device in numerous locations in North America, and India.”
